GlassScriptPhysician profile
Lewis Tsai
NPI 1538620810
$505.39
in general payments reported to CMS, 2019-2025
14 companies · $505 in 2025
The $505 reported for 2025 was more than what 83% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $83.94 | 2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $80.29 | 2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $62.77 | 2025 | Jardiance, Zepbound, Mounjaro |
| Corium, LLC | $42.43 | 2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $35.55 | 2025 | |
| Pfizer INC. | $28.23 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.40 | 2025 | |
| Exact Sciences Corporation | $24.58 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $24.00 | 2025 | Sunosi |
| Agios Pharmaceuticals, INC. | $23.82 | 2025 | Pyrukynd |
| Globus Medical, INC. | $19.91 | 2025 | Senza |
| Amneal Pharmaceuticals LLC | $19.82 | 2025 | Crexont |
| Kowa Pharmaceuticals America, INC. | $17.52 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $17.13 | 2025 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.